In search of treatment alternatives, we also hypothesise that in basal-like tumours, since upregulation of the PLAU group has higher hypoxia scores and higher immunosuppressive tumour signatures (PD-L1 and PD-L2) than the anti-tumour immune signature (CD8+ T cells), which may be predictive of immunotherapy (in combination with uPA and plus-minus chemotherapy) in this chemo resistant. The gene discussed is PDCD1LG2; the disease is neoplasm.